NEW YORK, Feb 6 – Lexicon said Tuesday it has licensed its gene targeting technology to Immunex, bringing to 14 the number of its sublicensees.

Under the terms of the deal, Lexicon will receive annual license fees, technology usage frees for any model Immunex develops using the technology, as well as milestone payments for future discoveries.

Exact figures were not disclosed.

Lexicon of The Woodlands, Tex., determines gene function using large-scale knockout mouse technology.